- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Identity development.
Displaying page 1 of 1.
EudraCT Number: 2008-003251-74 | Sponsor Protocol Number: 62/2008/U/Sper | Start Date*: 2008-06-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: ROLE OF TESTOSTERONE AND ITS METABOLITE DIHYDROTESTOSTERONE ON METABOLISM AND ON MUSCLE STRENGTH IN SUBJECTS AFFECTED BY GENEDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS) | |||||||||||||
Medical condition: GENDER IDENTITY DISORDER (GID) (FtM TRANSSEXUALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005688-18 | Sponsor Protocol Number: Paw1 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:Department of Hematology, Aalborg University Hospital | |||||||||||||
Full Title: A randomized controlled trial of alendronate as preventive treatment against the development of gluco-corticoid-induced osteoporosis in patients being treated for malignant lymphoma | |||||||||||||
Medical condition: Age ≥ 18 years. Patients with new diagnosis or recurrence of lymphoma, which is expected to be treated with one of the listed chemotherapy regimens. Expected lifespan ≥2 years | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001070-29 | Sponsor Protocol Number: CRF005 | Start Date*: 2023-05-26 | |||||||||||
Sponsor Name:Chelsea and Westminster NHS Foundation Trust | |||||||||||||
Full Title: Efficacy, tolerability and acceptability of the single tablet regimen (STR) Biktarvy® by trans people living with HIV (TPLWH) | |||||||||||||
Medical condition: Human Immunodeficiency Virus (HIV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002337-11 | Sponsor Protocol Number: Pub-01 | Start Date*: 2013-02-07 | |||||||||||
Sponsor Name:Västra Götalandsregionen (VGR) [...] | |||||||||||||
Full Title: A multicenter and randomised clinical study on pubertal replacement therapy in boys - Treatment of boys with absent or delayed puberty with rhFSH and two different formulations of testosterone in l... | |||||||||||||
Medical condition: Delayed or absence of puberty | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004274-87 | Sponsor Protocol Number: NV-02B-022 / CLDT600A2303 | Start Date*: 2005-09-30 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies | |||||||||||||
Medical condition: chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004605-27 | Sponsor Protocol Number: GS-US-494-5484 | Start Date*: 2020-10-28 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects with Advanced Solid Tumors | |||||||||||||
Medical condition: Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001941-28 | Sponsor Protocol Number: R092670PSY3015 | Start Date*: 2018-02-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6 Month Formulation. | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) CZ (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004532-30 | Sponsor Protocol Number: R092670PSY3016 | Start Date*: 2019-08-09 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Single-arm, Open-label Extension to a Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019925-33 | Sponsor Protocol Number: D4130C00003 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in ... | ||||||||||||||||||
Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FI (Completed) SE (Completed) LT (Completed) EE (Completed) LV (Completed) CZ (Completed) FR (Completed) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-020140-36 | Sponsor Protocol Number: D4130C00005 | Start Date*: 2010-09-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepress... | |||||||||||||
Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy. Complemento de un antidepresivo en pacientes con tras... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) SK (Completed) FR (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
